viernes, 5 de junio de 2020

Have you seen the latest news and insights on Cystic Fibrosis News Today?


Cystic Fibrosis Weekly Update

Contents:

Encala Improves Fat Absorption in CF Patients With Pancreatic Insufficiency, Study Shows

Jun 05, 2020 07:00 am | David Melamed, PhD



Elexacaftor, CFInvestigational treatment Encala (Lym-X-Sorb) is safe, well tolerated, and increased dietary fat absorption in patients with cystic fibrosis (CF) and pancreatic insufficiency, according to an analysis from a Phase 2 clinical trial. Findings from the analysis were reported in the study, “Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a […]
The post Encala Improves Fat Absorption in CF Patients With Pancreatic Insufficiency, Study Shows appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Encala Improves Fat Absorption in CF Patients With Pancreatic Insufficiency, Study Shows on Facebook

Microbion Awarded $17M to Advance Inhaled Antimicrobial Pravibismane for Lung Infections

Jun 04, 2020 07:00 am | Ines Martins, PhD



Microbion and CARB-XMicrobion has been awarded up to $17.1 million from the nonprofit CARB-X and the Cystic Fibrosis Foundation to complete preclinical and Phase 1 clinical studies of its inhaled antimicrobial medication pravibismane for treating cystic fibrosis (CF) patients with lung infections. CARB-X — Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator — is a global partnership launched in 2016 […]
The post Microbion Awarded $17M to Advance Inhaled Antimicrobial Pravibismane for Lung Infections appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Microbion Awarded $17M to Advance Inhaled Antimicrobial Pravibismane for Lung Infections on Facebook

Recent News

Georgia College Student Receives AffloVest from Legacy Project
CF Registry in UK Collecting Data on COVID-19 Infections
Why My Service Dog Is Staying Home
Pravibismane Receives FDA Orphan Drug Status for Treatment of CF Lung Infections
COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

No hay comentarios:

Publicar un comentario